Item 2.02. Results of Operations and Financial Condition.

On January 9, 2023, Kiniksa Pharmaceuticals, Ltd. (the "Company") issued a press release announcing, among other things, that (i) its preliminary year-end 2022 cash, cash equivalents and short-term investments of $190.4 million (unaudited) are expected to fund its current operating plan into at least 2025 and (ii) ARCALYST net revenue was $39.9 million and $122.5 million for the fourth quarter and full year 2022, respectively (unaudited). A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.

The preliminary selected financial results reported by the Company are unaudited, subject to adjustment, and provided as an approximation in advance of the Company's announcement of complete financial results in February 2023.

The information contained in this Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing and except as expressly provided by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits



Exhibit
No.                                        Description

  99.1       Press Release of Kiniksa Pharmaceuticals, Ltd., dated January 9, 2023

104        Cover Page Interactive Data File (embedded within the inline XBRL document)

© Edgar Online, source Glimpses